What do systematic reviews say?

PREFRONTAL TMS vs SHAM TMS

• Transcranial magnetic stimulation (TMS) for schizophrenia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 199 participants
  Low

PREFRONTAL TBS TMS vs SHAM TMS

• Transcranial magnetic stimulation (TMS) for schizophrenia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 27 participants
  Low

TEMPOROPARIETAL TMS vs SHAM TMS

• Transcranial magnetic stimulation (TMS) for schizophrenia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  11 studies · 442 participants
  Low

Adalimumab weekly vs placebo

Adalimumab weekly showed no clear difference in frequency of serious adverse effects compared with placebo (moderate certainty).

• Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
  RR 2 [0.38, 10.44]
  1 study · 102 participants
  Moderate

Adalimumab every other week vs placebo

Adalimumab every other week showed no clear difference in frequency of serious adverse effects compared with placebo (high certainty).

• Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
  RR 1.47 [0.26, 8.44]
  2 studies · 124 participants
  High

Chlorhexidine (vaginal wash or gel/cream) vs placebo or no treatment

It is very uncertain whether chlorhexidine (vaginal wash or gel/cream) changes adverse (mild) effects in the mother compared with placebo or no treatment (very low certainty).

• Vaginal chlorhexidine during labour to prevent early‐onset neonatal group B streptococcal infection 2014 · Cochrane Headline outcomes only
  RR 8.5 [1.6, 45.28]
  3 studies · 1066 participants
  Very low

PHYSICAL HEALTH ADVICE vs usual care

PHYSICAL HEALTH ADVICE showed no clear difference in adverse effects Death of participant compared with STANDARD CARE (low certainty).

• General physical health advice for people with serious mental illness 2014 · Cochrane Headline outcomes only
  RR 0.98 [0.27, 3.56]
  2 studies · 487 participants
  Low

Bromperidol decanoate vs other depot antipsychotic drugs

It is very uncertain whether bromperidol decanoate changes adverse effects ‐ movement disorders compared with other depot antipsychotic drugs (very low certainty).

• Bromperidol decanoate (depot) for schizophrenia 2012 · Cochrane Headline outcomes only
  RR 0.74 [0.47, 1.17]
  2 studies · 77 participants
  Very low

Intervention not reported

• Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression 2012 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 28 participants
  Low

Intervention not reported

• Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression 2012 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 291 participants
  Low

Intervention not reported

The review found no eligible studies for this question.

• Home‐based child development interventions for preschool children from socially disadvantaged families 2011 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Topical aminocaproic acid vs placebo

The review found no eligible studies for this question.

• Medical interventions for traumatic hyphema 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Oestrogen therapy alone vs pelvic floor muscle training (PFMT)

The review found no eligible studies for this question.

• Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Oestrogen therapy alone vs devices such

The review found no eligible studies for this question.

• Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Oestrogen therapy alone vs surgery

The review found no eligible studies for this question.

• Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Oestrogen therapy alone vs no treatment or placebo

The review found no eligible studies for this question.

• Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Standard treatment plus systemic corticosteroids vs usual care

It is very uncertain whether standard treatment plus systemic corticosteroids changes adverse effects: exposure keratopathy compared with standard treatment alone (very low certainty).

• Corticosteroids for periorbital and orbital cellulitis 2021 · Cochrane Headline outcomes only
  RR 1.2 [0.4, 3.63]
  1 study · 21 participants
  Very low

Laparoscopic colposuspension vs midurethral sling procedures

The review found no eligible studies for this question.

• Laparoscopic colposuspension for urinary incontinence in women 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Laparoscopic colposuspension with one suture vs laparoscopic colposuspension with two sutures

The review found no eligible studies for this question.

• Laparoscopic colposuspension for urinary incontinence in women 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Laparoscopic colposuspension with sutures vs laparoscopic colposuspension with mesh and staples

The review found no eligible studies for this question.

• Laparoscopic colposuspension for urinary incontinence in women 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found